Cargando…

Extracorporeal shockwave therapy in musculoskeletal disorders

The sources of shockwave generation include electrohydraulic, electromagnetic and piezoelectric principles. Electrohydraulic shockwaves are high-energy acoustic waves generated under water explosion with high voltage electrode. Shockwave in urology (lithotripsy) is primarily used to disintegrate uro...

Descripción completa

Detalles Bibliográficos
Autor principal: Wang, Ching-Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342893/
https://www.ncbi.nlm.nih.gov/pubmed/22433113
http://dx.doi.org/10.1186/1749-799X-7-11
_version_ 1782231744918847488
author Wang, Ching-Jen
author_facet Wang, Ching-Jen
author_sort Wang, Ching-Jen
collection PubMed
description The sources of shockwave generation include electrohydraulic, electromagnetic and piezoelectric principles. Electrohydraulic shockwaves are high-energy acoustic waves generated under water explosion with high voltage electrode. Shockwave in urology (lithotripsy) is primarily used to disintegrate urolithiasis, whereas shockwave in orthopedics (orthotripsy) is not used to disintegrate tissues, rather to induce tissue repair and regeneration. The application of extracorporeal shockwave therapy (ESWT) in musculoskeletal disorders has been around for more than a decade and is primarily used in the treatment of sports related over-use tendinopathies such as proximal plantar fasciitis of the heel, lateral epicondylitis of the elbow, calcific or non-calcific tendonitis of the shoulder and patellar tendinopathy etc. The success rate ranged from 65% to 91%, and the complications were low and negligible. ESWT is also utilized in the treatment of non-union of long bone fracture, avascular necrosis of femoral head, chronic diabetic and non-diabetic ulcers and ischemic heart disease. The vast majority of the published papers showed positive and beneficial effects. FDA (USA) first approved ESWT for the treatment of proximal plantar fasciitis in 2000 and lateral epicondylitis in 2002. ESWT is a novel non-invasive therapeutic modality without surgery or surgical risks, and the clinical application of ESWT steadily increases over the years. This article reviews the current status of ESWT in musculoskeletal disorders.
format Online
Article
Text
id pubmed-3342893
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33428932012-05-04 Extracorporeal shockwave therapy in musculoskeletal disorders Wang, Ching-Jen J Orthop Surg Res Review The sources of shockwave generation include electrohydraulic, electromagnetic and piezoelectric principles. Electrohydraulic shockwaves are high-energy acoustic waves generated under water explosion with high voltage electrode. Shockwave in urology (lithotripsy) is primarily used to disintegrate urolithiasis, whereas shockwave in orthopedics (orthotripsy) is not used to disintegrate tissues, rather to induce tissue repair and regeneration. The application of extracorporeal shockwave therapy (ESWT) in musculoskeletal disorders has been around for more than a decade and is primarily used in the treatment of sports related over-use tendinopathies such as proximal plantar fasciitis of the heel, lateral epicondylitis of the elbow, calcific or non-calcific tendonitis of the shoulder and patellar tendinopathy etc. The success rate ranged from 65% to 91%, and the complications were low and negligible. ESWT is also utilized in the treatment of non-union of long bone fracture, avascular necrosis of femoral head, chronic diabetic and non-diabetic ulcers and ischemic heart disease. The vast majority of the published papers showed positive and beneficial effects. FDA (USA) first approved ESWT for the treatment of proximal plantar fasciitis in 2000 and lateral epicondylitis in 2002. ESWT is a novel non-invasive therapeutic modality without surgery or surgical risks, and the clinical application of ESWT steadily increases over the years. This article reviews the current status of ESWT in musculoskeletal disorders. BioMed Central 2012-03-20 /pmc/articles/PMC3342893/ /pubmed/22433113 http://dx.doi.org/10.1186/1749-799X-7-11 Text en Copyright ©2012 Wang; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Wang, Ching-Jen
Extracorporeal shockwave therapy in musculoskeletal disorders
title Extracorporeal shockwave therapy in musculoskeletal disorders
title_full Extracorporeal shockwave therapy in musculoskeletal disorders
title_fullStr Extracorporeal shockwave therapy in musculoskeletal disorders
title_full_unstemmed Extracorporeal shockwave therapy in musculoskeletal disorders
title_short Extracorporeal shockwave therapy in musculoskeletal disorders
title_sort extracorporeal shockwave therapy in musculoskeletal disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342893/
https://www.ncbi.nlm.nih.gov/pubmed/22433113
http://dx.doi.org/10.1186/1749-799X-7-11
work_keys_str_mv AT wangchingjen extracorporealshockwavetherapyinmusculoskeletaldisorders